| Synonym |
| Thai / English name |
Part Used : น้ำจากผลActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : 3,3',4',5,6,7,8-heptamethoxyflavone (HMF)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Uptake experiments were performed in 250 ml of incubation buffer containing 20 mM [3H]vinblastine in the presence of HMF 20 microMDuration : 60 min.Type of interaction : PharmacokineticsInteraction with drug : Vinblastine*/VLBDose/Conc.(drug) : 20 mM [3H]vinblastineResult : PositiveRemark : Result: In LLC-PK1 cells, the uptake of [3H]vinblastine at steady state was not influenced by 10 mM cyclosporin A, HMF, tangeretin, or nobiletin.
Part Used : น้ำจากผลActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : tangeretinType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Uptake experiments were performed in 250 ml of incubation buffer containing 20 mM [3H]vinblastine in the presence of tangeretin 20 microMDuration : 60 min.Type of interaction : PharmacokineticsInteraction with drug : Vinblastine*/VLBDose/Conc.(drug) : 20 mM [3H]vinblastineResult : PositiveRemark : Result: In LLC-PK1 cells, the uptake of [3H]vinblastine at steady state was not influenced by 10 mM cyclosporin A, HMF, tangeretin, or nobiletin.
Part Used : น้ำจากผลActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : nobiletinType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Uptake experiments were performed in 250 ml of incubation buffer containing 20 mM [3H]vinblastine in the presence of nobitetin 20 microMDuration : 60 min.Type of interaction : PharmacokineticsInteraction with drug : Vinblastine*/VLBDose/Conc.(drug) : 20 mM [3H]vinblastineResult : PositiveRemark : Result: In LLC-PK1 cells, the uptake of [3H]vinblastine at steady state was not influenced by 10 mM cyclosporin A, HMF, tangeretin, or nobiletin.
Part Used : น้ำจากผลActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : 3.3',4',5,6,7,8-heptamethoxyflavone (HMF)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Uptake experiments were performed in 250 ml of incubation buffer containing 20 mM [3H]vinblastine in the presence of HMF 20 microMDuration : 60 min.Type of interaction : PharmacokineticsInteraction with drug : Vinblastine*/VLBDose/Conc.(drug) : 20 mM [3H]vinblastineResult : PositiveRemark : Result: In LLC-GA5-COL300 cells, the uptake of [3H]vinblastine at steady state was significantly increased by 20 microM HMF (99.8 +/- 4.61 microliter/mg of protein) compared with the control (10.6 +/- 0.612 microliter/mg of protein).
Part Used : น้ำจากผลActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : tangeretinType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Uptake experiments were performed in 250 ml of incubation buffer containing 20 mM [3H]vinblastine in the presence of tangeretin 20 microMDuration : 60 min.Type of interaction : PharmacokineticsInteraction with drug : Vinblastine*/VLBDose/Conc.(drug) : 20 mM [3H]vinblastineResult : PositiveRemark : Result: In LLC-GA5-COL300 cells, the uptake of [3H]vinblastine at steady state was significantly increased by 20 microM tangeretin (64.5 +/- 1.66 microliter/mg of protein) compared with the control (10.6 +/- 0.612 microliter/mg of protein).
Part Used : น้ำจากผลActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : nobiletinType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Uptake experiments were performed in 250 ml of incubation buffer containing 20 mM [3H]vinblastine in the presence of nobiletin 20 microMDuration : 60 min.Type of interaction : PharmacokineticsInteraction with drug : Vinblastine*/VLBDose/Conc.(drug) : 20 mM [3H]vinblastineResult : PositiveRemark : Result: In LLC-GA5-COL300 cells, the uptake of [3H]vinblastine at steady state was significantly increased by 20 microM nobiletin (18.6 +/- 2.05 microliter/mg of protein) compared with the control (10.6 +/- 0.612 microliter/mg of protein).
Part Used : น้ำจากผลActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : orange juiceType of experiment : humanType of animal : -Type of study : Open trialN(Total) : 15* (M/F = 8/7)N(Treatment) : 15 (M/F = 8/7)Sex : Both sexAge : >/= 18 yrs.Route : Oral administrationDose/Conc.(herb) : A single 500 mg tablet of ciprofloxacin with 12 ounces of orange juiceDuration : Blood samples were collected predose (baseline) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours after each ciprofloxacin administration.Type of interaction : PharmacokineticsInteraction with drug : CiprofloxacinDose/Conc.(drug) : A single 500 mg tablet of ciprofloxacinResult : PositiveRemark : Result: When ciprofloxacin was taken with nonfortified orange juice, the Cmax and AUC 24 of the ciprofloxacin dose decreased by 23% (p = 0.001) and 21.6% (p < 0.001), respectively, as compared to when it was taken with water.Note : Although ciprofloxacin is marginally bioequivalent when administered with orange juice, it is not when it is administered with calcium-fortified orange juice. The changes in Cmax and AUC have the potential to significantly decrease clinical efficacy and promote antibiotic resistance. Not warning patients about potential food-drug interactions with fortified foods may be a major unrealized and unstudied inadvertent source of clinical failures and resistance trends with fluoroquinolones. Subject total: Subjects were healthy volunteers.
Part Used : น้ำจากผลActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : orange juiceType of experiment : humanType of animal : -Type of study : Cross overN(Total) : 15* (M/F = 8/7)N(Treatment) : 15 (M/F = 8/7)Sex : Both sexAge : >/= 18 yrs.Route : Oral administrationDose/Conc.(herb) : A single 500 mg tablet of ciprofloxacin with 12 ounces of orange juiceDuration : Blood samples were collected predose (baseline) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours after each ciprofloxacin administration.Type of interaction : PharmacokineticsInteraction with drug : CiprofloxacinDose/Conc.(drug) : A single 500 mg tablet of ciprofloxacinResult : PositiveRemark : Result: When ciprofloxacin was taken with nonfortified orange juice, the Cmax and AUC 24 of the ciprofloxacin dose decreased by 23% (p = 0.001) and 21.6% (p < 0.001), respectively, as compared to when it was taken with water.Note : Although ciprofloxacin is marginally bioequivalent when administered with orange juice, it is not when it is administered with calcium-fortified orange juice. The changes in Cmax and AUC have the potential to significantly decrease clinical efficacy and promote antibiotic resistance. Not warning patients about potential food-drug interactions with fortified foods may be a major unrealized and unstudied inadvertent source of clinical failures and resistance trends with fluoroquinolones. Subject total: Subjects were healthy volunteers.
Part Used : น้ำจากผลActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : calcium-fortified orange juiceType of experiment : humanType of animal : -Type of study : Open trialN(Total) : 15* (M/F = 8/7)N(Treatment) : 15 (M/F = 8/7)Sex : Both sexAge : >/= 18 yrs. (mean 38.8 +/- 8.1)Route : Oral administrationDose/Conc.(herb) : A single 500 mg tablet of ciprofloxacin with 12 ounces of orange juice fortified with calcium.Duration : Blood samples were collected predose (baseline) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours after each ciprofloxacin administration.Type of interaction : PharmacokineticsInteraction with drug : CiprofloxacinDose/Conc.(drug) : A single 500 mg tablet of ciprofloxacinResult : PositiveRemark : Result: When ciprofloxacin was taken with calcium-fortified orange juice, Cmax and AUC24 decreased by 41% (p < 0.001) and 38% (p < 0.001), respectively, as compared to when taken with water.Note : Although ciprofloxacin is marginally bioequivalent when administered with orange juice, it is not when it is administered with calcium-fortified orange juice. The changes in Cmax and AUC have the potential to significantly decrease clinical efficacy and promote antibiotic resistance. Not warning patients about potential food-drug interactions with fortified foods may be a major unrealized and unstudied inadvertent source of clinical failures and resistance trends with fluoroquinolones. Subject total: Subjects were healthy volunteers.
Part Used : น้ำจากผลActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : calcium-fortified orange juiceType of experiment : humanType of animal : -Type of study : Cross overN(Total) : 15* (M/F = 8/7)N(Treatment) : 15 (M/F = 8/7)Sex : Both sexAge : >/= 18 yrs. (mean 38.8 +/- 8.1)Route : Oral administrationDose/Conc.(herb) : A single 500 mg tablet of ciprofloxacin with 12 ounces of orange juice fortified with calcium.Duration : Blood samples were collected predose (baseline) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours after each ciprofloxacin administration.Type of interaction : PharmacokineticsInteraction with drug : CiprofloxacinDose/Conc.(drug) : A single 500 mg tablet of ciprofloxacinResult : PositiveRemark : Result: When ciprofloxacin was taken with calcium-fortified orange juice, Cmax and AUC24 decreased by 41% (p < 0.001) and 38% (p < 0.001), respectively, as compared to when taken with water.Note : Although ciprofloxacin is marginally bioequivalent when administered with orange juice, it is not when it is administered with calcium-fortified orange juice. The changes in Cmax and AUC have the potential to significantly decrease clinical efficacy and promote antibiotic resistance. Not warning patients about potential food-drug interactions with fortified foods may be a major unrealized and unstudied inadvertent source of clinical failures and resistance trends with fluoroquinolones. Subject total: Subjects were healthy volunteers.
